In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Selected Start-Ups (09/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: Ardana Bioscience Ltd., spun-out in July from Britain's Medical Research Council, will commercialize research related to contraception and women's health. DiscoveRx will use proprietary enzyme fragment technology originally developed for clinical assays for SNP detection, to identify and validate drug targets, screen for drug leads, and collect pharmakinetic data on drugs in development. Fluorous Technologies Inc. was formed in June to commercialize fluorous organic chemistry technology developed by University of Pittsburgh chemistry professor Dennis P. Curran, PhD. Created by the founders of Geneva Bioinformatics Inc., Geneva Proteomics Inc. will obtain proteomic data by analyzing biologic fluids and tissues in health and sick individuals, enhance the data through bioinformatics, and sell information and synthesized proteins to clients. Hyalose LLC will commercialize unique recombinant technology developed by Paul H. Weigel, PhD and Paul L. DeAngelis, PhD at the University of Oklahoma Health Sciences Center (OUHSC) for the production of designer hyaluronan and novel polysaccharides. CMEA, Bay City, MPM and Versant are backing Syrrx Inc., a new entrant in the structural genomics field.

You may also be interested in...

Viatris Will Tread A Different Path

By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.

EU Single Patent System On Course For 2020

Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.

Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA

A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts